Clinical trial with a genetically modified Vaccinia virus based treatment for solid cancerous tumours
Inadvertent dealings with genetically modified soybean
Details of OGTR monitoring and compliance activities during the quarter ended 31 March 2023.
Commercial release of banana genetically modified for resistance to Fusarium wilt tropical race 4 (TR4)
This infographic gives a brief description of the difference between OGTR and FSANZ regulatory remits, where the OGTR conducts risk analysis and licensing for commercial cultivation, while FSANZ conducts food safety assessments, approves food for sale and sets labelling requirements.
Clinical trial of genetically modified Lactobacillus brevis for treatment of inflammatory bowel disease
Commercial supply of Qdenga, a live attenuated GM dengue vaccine
This is a hypothetical case study provided as an example. It should not be cited as evidence in an application. Although the data and discussions are representative, this example may not include all considerations needed when assessing risks from a proposed GM plant limited and controlled release.
Commercial release of canola genetically modified for herbicide tolerance and a hybrid breeding system (MS11× RF3 and MS11 × RF3 × MON 88302)
Documents supporting applications for the certification of Physical Containment Level 1 (PC1) facilities.